An emerging interest in targeting IL-33 and its receptor ST2 with pharmacological treatments in individuals with respiratory diseases including asthma can be seen with examples such as SAR440340 (ClinicalTrials.gov identifier, NCT03546907) from Regeneron Pharmaceuticals and Sanofi, MSTT1041A (ClinicalTrials.gov Identifier: NCT02918019) from Hoffmann-La Roche, GSK3772847 (ClinicalTrials.gov Identifier: NCT03207243) from GlaxoSmithKline and etokimab (ClinicalTrials.gov Identifier: NCT03469934) from AnaptysBio. The gene discussed is IL33; the disease is respiratory system disorder.